Issue 10, 2024

Thiochromenocarbazole imide-based photosensitizers decorated with carbonic anhydrase inhibitors for the targeted treatment of hypoxic tumours

Abstract

PDT has gained growing interest as a prospective approach for cancer therapy, thanks to its minimal invasiveness and low systemic toxicity, making it a promising therapeutic option. Nevertheless, type II PDT is significantly influenced by the oxygen levels in the tumoral microenvironment. Consequently, the weak oxygen pressure encountered in hypoxic regions of solid tumours poses a significant challenge in cancer treatment. In this case, PDT efficiency is reduced and the existing hypoxia is intensified by oxygen consumption and vascular closure, activating the angiogenic factors and thus, potentially leading to cancer recurrence and progression. We describe here a series of thiochromenocarbazole imide (TCI) photosensitizers featuring carbonic anhydrase inhibitors (CAi) of the sulfonamide, coumarin and sulfocoumarine type, designed to alleviate the consequences of PDT-induced hypoxia by merging the advantages of hCA IX knockdowns with PDT. TCIs with coumarin and sulfocoumarin moieties showed selective inhibition against tumour-associated hCA IX and hCA XII, while TCI incorporating benzenesulfonamide moieties also showed activity against the off-target hCA II. In biological assays, the TCI photosensitizer incorporating coumarin-based CAi demonstrated minimal dark toxicity and showcased strong imaging and photodynamic therapy (PDT) effects in both in vitro and in vivo settings.

Graphical abstract: Thiochromenocarbazole imide-based photosensitizers decorated with carbonic anhydrase inhibitors for the targeted treatment of hypoxic tumours

Supplementary files

Article information

Article type
Paper
Submitted
29 10月 2023
Accepted
08 2月 2024
First published
21 2月 2024
This article is Open Access
Creative Commons BY-NC license

Mater. Adv., 2024,5, 4172-4177

Thiochromenocarbazole imide-based photosensitizers decorated with carbonic anhydrase inhibitors for the targeted treatment of hypoxic tumours

A. Merabti, D. P. Sánchez, A. Nocentini, L. M. A. Ali, C. Nguyen, D. Durand, K. Hamon, T. Ghanem, P. Arnoux, P. Josse, C. Frochot, R. Zalubovskis, S. Richeter, M. Gary-Bobo, C. T. Supuran, C. Cabanetos, J. Winum and S. Clément, Mater. Adv., 2024, 5, 4172 DOI: 10.1039/D3MA00926B

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements